News

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...
A European consensus statement says antithrombotic treatment for acute coronary syndromes should adjust for sex differences ...
The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...
Aurobindo Pharma shares fell 4.67 per cent to hit a high of Rs 1,039.30 on BSE, commanding a market capitalisation of just ...
Reports suggested it has emerged as the frontrunner to acquire Prague-based Zentiva for $5 to $5.5 billion. If completed, this would be the largest-ever acquisition by an Indian pharma company.
Aurobindo Pharma shares fell nearly 5% to ₹1,039 amid reports it may acquire Zentiva for $5-5.5 billion. This would be the ...
After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...
Aurobindo Pharma has reportedly emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5–5.5 ...
On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...
Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...
The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...
Aurobindo Pharma said it 'regularly explores' various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value.